Stem Cell Exosome Production Under Shear for Cardiac Scar Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic cardiomyopathy, such as stem cell injection therapies, face challenges with poor retention and engraftment of stem cells at the infarct site, leading to limited therapeutic efficacy due to the high cost and scarcity of adult cardiac stem cells, which are crucial for regenerating cardiac muscle and preventing scar tissue growth.
Innovation Solution
The production of injectable enhanced stem cell exosomes (IESCE) under pulsatile fluid-induced oscillatory shear stresses in a bioreactor, which enhances the secretion of cytokines and growth factors, mimicking pathological conditions to promote cardiac tissue regeneration and inhibit scar tissue growth, using bioreactors to culture stem cells under pathologically high oscillatory flow conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult cardiac stem cells are used for cardiac tissue regeneration, then therapeutic efficacy is improved, but cost and scarcity increase
Solution Approach 1:
The patent creates exosomes that copy and carry the therapeutic functions of adult cardiac stem cells without requiring the actual cells. These exosomes replicate the regenerative capabilities through molecular cargo (proteins, lipids, RNA) that mimics stem cell activity, making the therapy scalable and cost-effective while maintaining therapeutic efficacy
Solution Approach 2:
The patent extracts the essential therapeutic components from adult cardiac stem cells by isolating and purifying exosomes that contain the beneficial molecules. This separation allows the therapeutic function to be delivered without the limitations of whole cell therapy, including scarcity and high cost
2Productivity
If pulsatile fluid-induced oscillatory shear stresses are applied in bioreactor, then exosome secretion is enhanced, but device complexity increases
Solution Approach 1:
The patent employs pulsatile fluid flow with oscillatory shear stresses applied in periodic cycles to the stem cells in the bioreactor. This periodic mechanical stimulation enhances exosome secretion by mimicking physiological flow conditions, increasing productivity while using a relatively simple bioreactor configuration
Solution Approach 2:
The patent uses hydraulic systems to generate and control the pulsatile fluid flow through the bioreactor. By utilizing fluid pressure and flow dynamics, the system achieves enhanced exosome secretion through controlled oscillatory shear stresses without requiring complex mechanical actuators
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IESCEs provide a non-living therapeutic agent that replicates the benefits of adult cardiac stem cells, enabling scalable production, effective cardiac tissue regeneration, and prevention of scar tissue growth without the limitations of cell survival, offering a cost-effective solution for treating cardiovascular diseases.
Implementation Method 1
production of injectable enhanced stem cell exosomes (IESCE) under pulsatile fluid-induced oscillatory shear stresses in a bioreactor
Data Source
AI summary
This disclosure pertains to a non-living biological product. Particularly, exosomes derived from stem cells can help prevent or reduce scar tissue growth in cardiovascular system and restore heart function. According to certain embodiments, a fluid-induced, pathological shear stress mechanical stimulation process of stem cells is used to augmented quantity and quality of exosomes produced from stem cells. These exosomes serve as a therapeutic agent for preventing or reducing scar tissue growth in cardiovascular system. Therefore, compositions comprising the exosomes derived from stem cells and methods of preventing and/or treating scar tissue growth in cardiovascular system by administering the exosomes isolated from stem cells are also provided.